Baseline D-dimer as a predictor of immune checkpoint inhibitor efficacy in cancer
Baseline D-dimer is a readily measurable, cost-effective biomarker that predicts inferior outcomes in patients receiving ICIs. Its integration into clinical workflows may aid patient stratification and guide treatment decisions. Prospective multicenter studies are warranted to validate cutoff thresholds and further define its utility in optimizing immunotherapy efficacy.
Authors
- Jie Zha (ORCID: https://orcid.org/0000-0001-9376-3450)
- W Zhang
- Meimei Hu
- Fan Li
Institutions
- Anqing Normal University (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1080/07853890.2026.2620195
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00